Tc-99m PSMA SPECT/CT for Prostate Cancer
Introduction
99mTc-PSMA SPECT/CT is a generator-based, gamma-camera method for imaging prostate-specific membrane antigen (PSMA) expression in prostate cancer, and it is often the most practical PSMA study for facilities that do not have ready access to PSMA PET. It pairs a Tc-99m-labeled PSMA ligand with whole-body planar imaging and regional SPECT/CT, and when reconstructed quantitatively it supports staging, biochemical-recurrence workup, bone-metastasis detection, response assessment, and selection of patients for PSMA-targeted therapy. 1, 2, 3
PSMA PET with Ga-68-PSMA-11 or an F-18-labeled ligand is the most sensitive molecular imaging modality for prostate cancer, but PET depends on a cyclotron or a generator for the positron emitter, on a PET/CT scanner, and on short-lived tracers that must be used quickly. Much of the world — and many community departments inside the United States — has a gamma camera but limited or intermittent PET access. 3, 8 Tc-99m solves several of those constraints at once: it is eluted from a Mo-99/Tc-99m generator that most nuclear medicine departments already run, it emits a single 140 keV photon that standard collimated cameras are optimized for, and its 6-hour half-life tolerates delayed imaging and even next-day surgical guidance. 1, 13
This guide explains the physics of 99mTc-PSMA SPECT/CT, how to build a defensible acquisition and reconstruction protocol, where it performs well and where it does not compared with PET, and the regulatory and quality considerations an imaging facility and its radiation safety officer should document. DRPS supports nuclear medicine programs across Florida, Maryland, Virginia, Washington DC, California, Nevada, Pennsylvania, New York, New Jersey, and Delaware through its PET/CT and nuclear medicine physics services.
Topic Explanation
What PSMA is and why it is a target
Prostate-specific membrane antigen is a type II transmembrane glycoprotein (glutamate carboxypeptidase II) that is overexpressed on the surface of most prostate cancer cells, with expression that tends to increase with higher grade, higher stage, and castration resistance. 1, 2 Its large extracellular domain is an accessible binding site, and small-molecule inhibitors that lock into the enzyme's active site can be radiolabeled to create imaging and therapy agents. That is the foundation of the PSMA "theranostic" concept: the same molecular target that a diagnostic ligand reports can be exploited by a therapeutic ligand such as Lu-177-PSMA-617. 3, 9
The Tc-99m-labeled PSMA ligands
Several Tc-99m-labeled PSMA inhibitors have been developed and studied clinically:
- 99mTc-PSMA-I&S ("imaging and surgery"), derived from the PSMA-I&T scaffold and adapted to kit-based Tc-99m labeling, designed for both SPECT imaging and radioguided surgery. 1
- 99mTc-MIP-1404 (trofolastat), a small-molecule PSMA inhibitor studied in large cohorts for biochemical recurrence. 2
- 99mTc-HYNIC-PSMA, a hydrazinonicotinamide-conjugated ligand used for primary tumor and metastasis detection. 6
- 99mTc-PSMA-T4, a kit-based ligand evaluated for recurrent disease. 9
All of them bind the extracellular domain of PSMA, are labeled with Tc-99m eluted from a generator, and are imaged on conventional SPECT or SPECT/CT systems. Normal physiologic uptake appears in the lacrimal and salivary glands, liver, spleen, kidneys, bowel, and urinary bladder, which is important to recognize when reading studies near the prostate bed. 9
Why Tc-99m changes the practical equation
Tc-99m is the workhorse radionuclide of nuclear medicine because its physics suits gamma-camera imaging almost perfectly: a single 140 keV photon that is efficiently collimated and detected, no therapeutic particle emission to add patient dose, and a 6-hour half-life that is long enough for delayed imaging but short enough to limit radiation burden. 13 Because it is generator-produced on site, a department can image PSMA without a cyclotron, without a Ga-68 generator, and without a PET scanner, using equipment and staff it already has. 3, 8
Key Technical Principles
Photon energy, collimation, and the resolution–sensitivity trade
A gamma camera forms an image by rejecting photons that do not travel along the collimator holes, so single-photon imaging inherently trades sensitivity for resolution. For the 140 keV photon of Tc-99m, a low-energy high-resolution (LEHR) parallel-hole collimator with a 140 keV ± 10% energy window is the standard choice, balancing spatial resolution against count sensitivity. PET, by contrast, uses electronic collimation (coincidence detection of two 511 keV photons), which is why PET achieves both higher sensitivity and higher spatial resolution than SPECT. 3, 8
The following comparison summarizes why the three PSMA imaging routes behave differently in practice.
| Feature | 99mTc-PSMA SPECT/CT | Ga-68-PSMA-11 PET/CT | F-18-PSMA PET/CT |
|---|---|---|---|
| Primary photon used for imaging | 140 keV single gamma | 511 keV annihilation pair | 511 keV annihilation pair |
| Physical half-life | ~6.0 h | ~68 min | ~110 min |
| Production / availability | Mo-99/Tc-99m generator on site | Ge-68/Ga-68 generator or cyclotron | Cyclotron (regional distribution) |
| Detector / collimation | Gamma camera, physical collimator | PET, electronic collimation | PET, electronic collimation |
| Relative spatial resolution and sensitivity | Lower | Higher | Higher |
| Typical injected activity (studied ranges) | ~230–740 MBq 3, 4, 5 | ~150–200 MBq 3 | Agent-specific |
| Supports delayed imaging / radioguided surgery | Yes (longer half-life) 1 | Limited (short half-life) | Limited |
| Relative cost and access | Lowest, most widely available 3, 8 | Higher | Higher |
The values above are representative of the published literature and should be confirmed against each facility's camera, software, and the specific ligand and prescribing information in use.
Acquisition protocol
Published 99mTc-PSMA protocols share a common structure: intravenous injection of the Tc-99m-PSMA ligand, a whole-body planar sweep, and then regional SPECT/CT over PSMA-positive or clinically suspicious regions. Reported injected activities span roughly 230–740 MBq depending on the ligand and institution — for example, 555–740 MBq in a comparative SPECT/CT versus PET/CT study, and about 740 MBq for 99mTc-HYNIC-PSMA. 3, 4, 5, 6 Imaging is typically performed about 3–4 hours after injection, and delayed imaging at 4–6 hours (or later) can disclose lesions not seen on earlier images because the lesion-to-background ratio continues to rise as background clears. 4, 1
Why SPECT/CT, not planar alone
The single most important protocol decision is to acquire tomographic, and ideally hybrid, images. In a study of 95 patients imaged with full-body planar plus multi-field-of-view SPECT/CT, pathologic prostatic uptake was seen in essentially all cases on SPECT/CT, in about 90% on SPECT, but in only about 15% on planar images; agreement between modalities for tumor–node–metastasis staging was good when SPECT or SPECT/CT was used. 8 The CT component adds anatomic localization and supplies the attenuation map and scatter information that quantitative reconstruction needs. The practical message is that SPECT/CT is recommended whenever available, and where only a single non-hybrid camera exists, SPECT still substantially outperforms planar imaging. 8
Quantitative SPECT and a worked SUV example
Modern SPECT/CT systems support absolute quantification, converting reconstructed counts into activity concentration and then into a standardized uptake value (SUV), analogous to PET. Investigators have reported quantitative 99mTc-PSMA SUV metrics and tumor-to-background ratios that correlate with prostate-specific antigen (PSA) level and Gleason score. 2, 6 The body-weight SUV is:
where
Consistent SUVs require consistent injected-activity measurement, accurate timing, and cross-calibration of the camera to the dose calibrator — exactly the chain a facility quality-control program must maintain.
Decay correction and why the 6-hour half-life matters
Quantification and delayed-imaging logistics both depend on correctly accounting for physical decay. Activity follows:
With
Clinical Impact
Primary staging and biochemical recurrence
In a prospective series using an enhanced SPECT/CT reconstruction algorithm, 99mTc-PSMA SPECT/CT achieved diagnostic performance for primary prostate cancer similar to both Ga-68-PSMA PET/CT and multiparametric MRI, and its positivity in biochemical recurrence rose with PSA level — from roughly 39% at PSA below 0.2 ng/mL to about 85% above 1.0 ng/mL. 5 In a 225-patient cohort imaged with 99mTc-MIP-1404, tracer-positive lesions were found in 77% of men, with detection rates of about 90% at PSA ≥ 2 ng/mL, and imaging changed management in a large fraction of documented cases. 2 These are the two clinical questions — where is the disease at diagnosis, and where has it recurred — that PSMA imaging most often answers.
Head-to-head with PSMA PET
Direct comparisons are candid about the trade-off. In a head-to-head study, 99mTc-PSMA SPECT/CT and Ga-68-PSMA PET/CT were both positive in about 95% of patients on a per-patient basis, but PET detected more individual regions (53 versus 43), with most of the SPECT shortfall occurring in the prostate bed. 3 In another comparison, Ga-68-PSMA PET/CT identified 112 PSMA-avid lesions versus 57 (51%) on 99mTc-PSMA, and notably 18 of those 57 lesions were visible only on delayed 99mTc-PSMA images. 4 The pattern is consistent: PET finds more small lesions, SPECT/CT captures most clinically relevant disease, and the gap narrows with SPECT/CT, delayed imaging, and optimized reconstruction. 3, 4, 5
Bone metastases and response assessment
For skeletal staging, 99mTc-PSMA compared favorably with the conventional 99mTc-MDP bone scan: in one prospective series it detected 52 of 55 bone lesions seen on MDP while adding information on nodal and visceral disease, and in one patient it changed management toward Lu-177-PSMA therapy. 7 Because PSMA imaging reports receptor expression rather than osteoblastic reaction, it can also support response monitoring after systemic or radioligand therapy. 3, 7
Theranostic selection and radioguided surgery
PSMA-avid disease must be confirmed before PSMA-targeted radioligand therapy, and 99mTc-PSMA SPECT/CT can demonstrate that expression where PET is unavailable, identifying candidates for Lu-177-PSMA. 3 Separately, 99mTc-PSMA-I&S enables radioguided surgery: after injection, a surgeon uses a handheld gamma probe to localize and resect PSMA-avid lymph nodes intraoperatively, a workflow first demonstrated in patients with proven nodal metastases and made practical by the 6-hour half-life and rising lesion-to-background ratios. 1
Practical Optimization Tips
A reliable 99mTc-PSMA program depends on a disciplined, documented protocol. The following steps support image quality and quantitative consistency.
1. Standardize injection and timing
Record net injected activity (syringe assay before and after injection), injection time, and imaging time for every patient. Decay-correct consistently and keep the delay interval reproducible so that serial studies and SUVs are comparable.
2. Optimize collimation and energy windows
Use an LEHR collimator and a symmetric 140 keV window appropriate to the camera, with scatter windows configured for the facility's scatter-correction method. Verify these settings during acceptance and at routine QC.
3. Always add SPECT, and CT when available
Acquire regional SPECT/CT over the pelvis and any planar-positive region, and over the abdomen or chest as the clinical question requires. Reserve planar-only reads for situations where tomography is genuinely impossible, and document that limitation. 8
4. Use iterative reconstruction with corrections
Reconstruct with an iterative algorithm (OSEM or a vendor resolution-recovery method) and apply CT-based attenuation correction and scatter correction. Where an enhanced or resolution-recovery reconstruction is validated for the ligand, it can meaningfully close the gap with PET. 5
5. Exploit delayed imaging
Add delayed images at 4–6 hours (or later) when early images are equivocal, because lesion-to-background ratios continue to improve and some lesions appear only on delayed acquisitions. 4
6. Maintain quantitative calibration
If SUVs are reported, cross-calibrate the camera to the dose calibrator, verify the calibration periodically with a traceable source, and document the quantitative QC chain. Treat quantitative SPECT with the same rigor PET departments apply to SUV.
Common pitfalls to avoid
- Reading planar images alone. Prostate-bed and many nodal lesions are missed without SPECT/CT. 8
- Ignoring delayed imaging. Early-only protocols miss lesions that emerge later. 4
- Over-reading near the bladder. Physiologic urinary activity can mask or mimic prostate-bed disease. 9
- Treating SPECT SUV casually. Quantification is only as good as the injected-activity measurement, timing, and camera calibration.
- Overstating equivalence to PET. For small-lesion and prostate-bed detection, PET remains more sensitive; set expectations accordingly. 3, 4
Regulatory Considerations
A 99mTc-PSMA program is a medical use of byproduct material, so it must be built on the facility's radioactive material license and the federal or Agreement State rules that govern it. Tc-99m is reactor- and generator-derived byproduct material, and its diagnostic use falls under the written-directive-exempt diagnostic framework rather than the therapy requirements that apply to Lu-177-PSMA. 11
Key frameworks to document against:
- 10 CFR Part 20 — Standards for Protection Against Radiation, including occupational and public dose limits, ALARA, surveys, and labeling that govern routine Tc-99m handling. 10
- 10 CFR Part 35 — Medical Use of Byproduct Material, including the authorized user and radiation safety officer structure, dose calibrator and instrument requirements, and recordkeeping. When the same program advances to Lu-177-PSMA therapy, the Part 35 therapy requirements (written directives, patient release, and training) apply to that therapy. 11
- NRC NUREG-1556, Volume 9 — program-specific guidance for medical-use licenses, including instrumentation, surveys, and radiation safety procedures. 12
- Patient radiation dose — diagnostic reference frameworks such as ICRP Publication 128 tabulate radiopharmaceutical dose coefficients and support dose optimization for Tc-99m diagnostic agents. 14
Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license medical use under their own radiation-control programs, while Washington, DC and Delaware are regulated directly by the NRC. A facility must verify which authority issues its license and which survey, instrument-calibration, and reporting requirements apply. Because the radiopharmaceuticals themselves are FDA-regulated drugs, the program should also confirm the regulatory status and prescribing information of the specific Tc-99m-PSMA ligand it uses, since availability and approval status vary by jurisdiction. 11
This work connects naturally to radioactive material license support, radiation safety officer consulting, and ongoing PET/CT and nuclear medicine physics.
Frequently Asked Questions (FAQs)
What is 99mTc-PSMA SPECT/CT?
It is a nuclear medicine study that uses a Tc-99m-labeled prostate-specific membrane antigen (PSMA) ligand, imaged on a standard gamma camera with whole-body planar imaging and regional SPECT/CT. It targets the same PSMA receptor as PSMA PET but uses the 140 keV photon of Tc-99m instead of a positron emitter, which makes it a lower-cost, more widely available option.
How is 99mTc-PSMA SPECT/CT different from Ga-68 or F-18 PSMA PET?
Both image PSMA expression. PET generally offers higher spatial resolution and sensitivity, so it detects more small lesions, especially in the prostate bed. 99mTc-PSMA uses a generator-produced single-photon tracer on existing gamma cameras, so it is cheaper and more accessible, has a longer 6-hour half-life that supports delayed imaging and radioguided surgery, but detects fewer small lesions than PET.
Which Tc-99m-labeled PSMA ligands are used?
Several have been studied, including 99mTc-PSMA-I&S (imaging and surgery), 99mTc-MIP-1404 (trofolastat), 99mTc-HYNIC-PSMA, and 99mTc-PSMA-T4. They differ in chemistry and biodistribution but all bind the extracellular domain of PSMA and are labeled with Tc-99m from a Mo-99/Tc-99m generator.
Can 99mTc-PSMA be used to select patients for Lu-177-PSMA therapy?
Yes. Confirming PSMA-avid disease is a prerequisite for PSMA-targeted radioligand therapy. Where PSMA PET is unavailable, 99mTc-PSMA SPECT/CT can demonstrate PSMA expression and help identify candidates for Lu-177-PSMA therapy, though PET remains the reference standard for theranostic selection.
Why is SPECT/CT preferred over planar imaging for 99mTc-PSMA?
Planar imaging alone misses most prostate-bed and many nodal lesions because of overlapping activity and limited contrast. SPECT, and especially SPECT/CT with anatomic localization and attenuation and scatter correction, substantially improves lesion detection and staging accuracy, so hybrid imaging is recommended whenever it is available.
What is 99mTc-PSMA radioguided surgery?
A patient is injected with 99mTc-PSMA-I&S before surgery, and the surgeon uses a handheld gamma probe to detect counts from PSMA-avid lymph nodes in the operating room. The 6-hour half-life of Tc-99m and high lesion-to-background ratios at delayed time points make Tc-99m well suited to intraoperative detection and targeted resection.
What are the main physics limitations of 99mTc-PSMA SPECT/CT?
Compared with PET, single-photon imaging has lower spatial resolution and sensitivity, collimation sacrifices counts for resolution, and absolute SPECT quantification is less standardized than PET SUV. High physiologic bladder and bowel activity can also obscure small prostate-bed lesions. Careful protocol design, delayed imaging, quantitative SPECT/CT, and a facility QC program mitigate these limits.
Key Takeaways
- 99mTc-PSMA SPECT/CT images the same PSMA target as PSMA PET using a generator-produced 140 keV single-photon tracer on a standard gamma camera, making it a lower-cost, widely available option. 1, 3
- PET is more sensitive for small lesions, but SPECT/CT captures most clinically relevant disease, and the gap narrows with hybrid imaging, delayed acquisitions, and optimized reconstruction. 3, 4, 5
- SPECT/CT is strongly preferred over planar imaging, which misses the majority of prostate-bed and many nodal lesions. 8
- The 6-hour half-life enables delayed imaging and radioguided surgery with 99mTc-PSMA-I&S and a handheld gamma probe. 1, 4
- Quantitative SPECT SUVs are feasible but demand careful injected-activity measurement, timing, and camera-to-dose-calibrator cross-calibration. 2, 6
- The program must be documented against 10 CFR Part 20, Part 35, and the applicable NRC or Agreement State requirements, including the FDA status of the specific ligand. 10, 11, 12
Conclusion
99mTc-PSMA SPECT/CT is not a second-rate PSMA PET — it is a different tool with its own physics, logistics, and best use cases. Where PET is unavailable, intermittent, or unaffordable, a well-designed Tc-99m-PSMA program lets a department stage high-risk disease, work up biochemical recurrence, assess the skeleton, confirm PSMA expression before radioligand therapy, and even guide surgery, all on equipment it already owns. The keys to getting it right are physics keys: appropriate collimation and energy windows, tomographic and hybrid acquisition, iterative reconstruction with attenuation and scatter correction, judicious delayed imaging, and a quantitative QC chain that makes SUVs trustworthy. Facilities that treat 99mTc-PSMA as a rigorously optimized study, not a fallback snapshot, get the most clinical value from it — and set themselves up cleanly for the theranostic pathway that often follows.
How DRPS Can Help
Diagnostic Radiation Physics Services helps nuclear medicine departments design, optimize, and document molecular imaging programs. For 99mTc-PSMA SPECT/CT this can include acquisition and reconstruction protocol development, collimator and energy-window verification, quantitative SPECT/CT calibration, gamma-camera and SPECT/CT acceptance and QC testing, radiation safety support for the generator and Tc-99m workflow, and license and RSO guidance aligned with NRC and Agreement State requirements through our radioactive material license support and radiation safety officer services.
DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.
When a department is ready to move from diagnostic PSMA imaging into PSMA-targeted therapy, the same team can help translate that step into a defensible, well-documented program.
Related Resources
- Ga-68 PSMA PET/CT imaging
- F-18 PSMA PET imaging
- Lu-177 PSMA therapy dosimetry and safety
- Quantitative SPECT/CT calibration
- Gamma camera collimator selection
- SPECT reconstruction: FBP and OSEM
- PET/CT and nuclear medicine physics services
- Radioactive material license support
References
- Robu S, Schottelius M, Eiber M, et al. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer. J Nucl Med. 2017;58(2):235-242. doi:10.2967/jnumed.116.178939. PubMed
- Schmidkonz C, Hollweg C, Beck M, et al. 99mTc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer. Prostate. 2018;78(1):54-63. doi:10.1002/pros.23444. PubMed
- Fallahi B, Khademi N, Karamzade-Ziarati N, et al. 99mTc-PSMA SPECT/CT Versus 68Ga-PSMA PET/CT in the Evaluation of Metastatic Prostate Cancer. Clin Nucl Med. 2021;46(2):e68-e74. doi:10.1097/RLU.0000000000003410. PubMed
- Singh B, Sharma S, Bansal P, et al. Comparison of the diagnostic utility of 99mTc-PSMA scintigraphy versus 68Ga-PSMA-11 PET/CT in the detection of metastatic prostate cancer and dosimetry analysis. Nucl Med Commun. 2021;42(5):482-489. doi:10.1097/MNM.0000000000001361. PubMed
- Duncan I, Ingold N, Martinez-Marroquin E, Paterson C. An Australian experience using Tc-PSMA SPECT/CT in the primary diagnosis of prostate cancer and for staging at biochemical recurrence after local therapy. Prostate. 2023;83(10):970-979. doi:10.1002/pros.24538. PubMed
- Wang T, Zhao L, Qiao W, Sun N, Zhao J, Xing Y. The efficacy of 99mTc-HYNIC-PSMA SPECT/CT in detecting primary lesions and metastasis in newly diagnosed prostate cancer. Front Oncol. 2023;13:1165694. doi:10.3389/fonc.2023.1165694. PubMed
- Kabunda J, Gabela L, Kalinda C, et al. Comparing 99mTc-PSMA to 99mTc-MDP in Prostate Cancer Staging of the Skeletal System. Clin Nucl Med. 2021;46(7):562-568. doi:10.1097/RLU.0000000000003702. PubMed
- Kolade OU, Brink A, Ayeni AO, More S, Holness J. Optimizing PSMA scintigraphy for resource limited settings — a retrospective comparative study. Cancer Imaging. 2024;24(1):46. doi:10.1186/s40644-024-00693-9. PubMed
- Sergieva S, Mangaldgiev R, Dimcheva M, et al. SPECT-CT Imaging with [99mTc]PSMA-T4 in patients with Recurrent Prostate Cancer. Nucl Med Rev Cent East Eur. 2021;24(2):70-81. doi:10.5603/NMR.2021.0018. PubMed
- U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation. ecfr.gov
- U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. ecfr.gov
- U.S. Nuclear Regulatory Commission. NUREG-1556, Volume 9, Revision 3: Program-Specific Guidance About Medical Use Licenses. nrc.gov
- International Commission on Radiological Protection. ICRP Publication 107: Nuclear Decay Data for Dosimetric Calculations. Annals of the ICRP. 2008;38(3). icrp.org
- International Commission on Radiological Protection. ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals. Annals of the ICRP. 2015;44(2S). icrp.org
Related Articles
-
Partial Volume Effect in Quantitative SPECT
The partial volume effect makes small structures read low in SPECT. Recovery coefficients restore the lost signal so activity, SUV, and therapy dosimetry stay accurate.
-
SPECT Scatter Correction: TEW, DEW, and Beyond
SPECT scatter correction explained: how triple- and dual-energy-window methods estimate and remove Compton scatter to restore contrast and enable quantitation.
-
Patient Release After Radiopharmaceutical Therapy
The 10 CFR 35.75 dose-based patient release rule: the 5 mSv limit, NUREG-1556 methods, dose calculations, written instructions, and recordkeeping.